Compare ENVX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | CSTL |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.7M | 722.8M |
| IPO Year | 2020 | 2019 |
| Metric | ENVX | CSTL |
|---|---|---|
| Price | $3.06 | $34.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $13.61 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 5.2M | 279.0K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,821,000.00 | ★ $344,229,000.00 |
| Revenue This Year | $30.37 | $2.42 |
| Revenue Next Year | $238.73 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.91 | 3.66 |
| 52 Week Low | $2.85 | $17.72 |
| 52 Week High | $14.21 | $44.28 |
| Indicator | ENVX | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 59.22 |
| Support Level | N/A | $22.88 |
| Resistance Level | $3.55 | $42.03 |
| Average True Range (ATR) | 0.15 | 1.42 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 15.00 | 61.55 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.